News

Rare Case of Post-COVID-19 Vaccine NMOSD Reported; No Causal Link

A 67-year-old man developed a rare case of neuromyelitis optica spectrum disorder (NMOSD) after his third dose of the COVID-19 vaccine, a study reports. A review of published literature showed this case adds to 15 other reported cases of post-COVID-19 vaccination NMOSD onset, which appear to show similar clinical…

Oval-Shaped Masses More Prevalent in Eyes of NMOSD Patients: Study

Adults with neuromyelitis optica spectrum disease (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein have a higher prevalence of oval-shaped masses surrounding the optic nerve in their eyes than healthy people, a study showed. Although these masses were significantly linked to older age, their occurrence was…

Case Report Describes NMOSD Rebound During Pregnancy

A young woman had a rebound of neuromyelitis optica spectrum disorder (NMOSD) toward the end of her pregnancy, for which she underwent plasma exchange and took steroids, according to a report from researchers in the U.S. Because treatment with plasma exchange and steroids did not work well enough, the…

ESR1 Gene Variations More Common in Women With NMOSD: Study

Certain variations in the ESR1 gene — a protein-coding gene for estrogen receptor-alpha — are significantly more common among women with neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS) than among healthy women, a small study suggests. Such differences were not observed between men with these…

#ECTRIMS2022 — Ultomiris Prevents Relapses in Clinical Trial

Ultomiris (ravulizumab) — Alexion Pharmaceuticals’ approved therapy for certain complement-associated disorders — prevents relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy also helped preserve walking skills, with treated patients showing a markedly lower risk of experiencing clinically…

#ECTRIMS2022 – Uplizna Helps Reduce Disease-driving Antibodies

Treatment with Uplizna (inebilizumab-cdon) can reduce levels of antibodies that drive neuromyelitis optica spectrum disorder (NMOSD), new clinical trial data show. The data also show that, among patients who aren’t on Uplizna, NMOSD attacks are often preceded by a sharp rise in levels of disease-driving antibodies and/or antibody-producing…

Inflammatory Neutrophils Resist Cell Death in AQP4 + NMOSD: Study

Neutrophils, a set of immune cells, from people with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) are resistant to certain forms of cell death, a study found. NMOSD patients also had increased blood levels of molecules that might help neutrophils resist cell death pathways. Similar findings weren’t observed…

High Incidence of Pain in NMOSD Is Mostly Nerve-related

The incidence of pain in adults with neuromyelitis optic spectrum disorder (NMOSD) is high and was reported as the first sign of an inflammatory attack in half of patients, according to an examination of medical records. Neuropathic (nerve-related) pain, marked by uncomfortable burning or tingling, was the most common…